In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $84.00. The company’s shares closed yesterday at $51.65.
Olson covers the Healthcare sector, focusing on stocks such as Biogen, Amgen, and Incyte. According to TipRanks, Olson has an average return of 16.8% and a 42.30% success rate on recommended stocks.
In addition to Oppenheimer, Incyte also received a Buy from Truist Financial’s Srikripa Devarakonda in a report issued today. However, on the same day, JMP Securities reiterated a Hold rating on Incyte (NASDAQ: INCY).
The company has a one-year high of $75.74 and a one-year low of $50.27. Currently, Incyte has an average volume of 1.75M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte (INCY) Company Description:
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
- Incyte to acquire Escient Pharmaceuticals for $750M
- Incyte initiated with a Neutral at Cantor on ‘lukewarm view’ of pipeline
- Incyte initiated with a Neutral at Cantor Fitzgerald
- Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
- Incyte, CMS enter collaboration, license agreement for povorcitinib in China
